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The Use of Dexamethasone vs Prednisone in the Treatment 
of Asthma Exacerbation 
 
Abstract 
 Asthma accounts for 2.1 million unscheduled ED visits annually, with a 
prevalence of 8.4% of the US population.2 Systemic corticosteroids serve as a 
cornerstone of acute asthma therapy, decreasing relapse rate, length of stay, and 
hospitalization rates. Since prednisone has multiple side effects and problematic 
compliance, studies have been conducted to determine if dexamethasone is as effective 
in the treatment of asthma exacerbation. This review evaluated a Cochrane systematic 
review, as well as three additional studies not included in that review. The conclusion 
was that dexamethasone is a promising alternative to prednisone in treating asthma 
exacerbation in both adults and children. However, in order for this possibility to be 
readily adopted into guidelines and clinical practice, higher quality and more consistent 
data needs to be obtained. 
Background 
Asthma is a chronic respiratory disease characterized by episodes or attacks of 
inflammation and narrowing of small airways.1 If asthma is not well controlled, then 
patients are at increased risk of an exacerbation serious enough to require a trip to the 
emergency department. The mechanism of an asthma exacerbation is via a 
combination of bronchospasm, hyperreactivity, and/or inflammation of the airways. 
Inflammation of the airways occurs via mast cell activation as a result of 
exposure to an allergen.11 Acute bronchoconstriction is the consequence of 
immunoglobulin E-dependent mediator release upon exposure to aeroallergens and is 
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the primary component of the early asthmatic response. Airway edema occurs 6-24 
hours following an allergen challenge and is referred to as the late asthmatic 
response.12 Hyperreactivity is a manifestation of reversible airflow obstruction due to 
smooth muscle contraction as an exaggerated constrictor response to a variety of 
physical, chemical, or environmental stimuli.11 Chronic inflammation of the airways is 
associated with increased bronchial hyperresponsiveness, which leads to 
bronchospasm and typical symptoms of wheezing, shortness of breath, and coughing.12  
Risk factors for an exacerbation vary greatly and include the following: 1) 
improper use of medications/inhalers, 2) under dosing of medications, and 3) indoor and 
outdoor environmental factors. In addition, endogenous sources can play a large role in 
exacerbations, including: 1) illness, 2) comorbidities, and 3) even strong emotions. 
Identifying and avoiding triggers, as well as optimization of preventive medication are 
part of controlling asthma symptoms and ultimately avoiding an exacerbation. 
Epidemiology 
According to the WHO, asthma is one of the major non-communicable diseases 
that affects people in all countries around the world.7 Two hundred thirty-five million 
people worldwide currently suffer from asthma, with 383,000 asthma-related deaths in 
2015.7 Asthma is under-diagnosed and under-treated. It creates substantial burden to 
individuals and families and often restricts individuals’ activities for a lifetime.7 The 
WHO’s strategy for prevention and control of asthma aims to reduce the disability and 
premature death related to asthma.7 
Data from the CDC show that asthma prevalence in the US has increased. In 
2005, the prevalence of asthma in the United States was nearly 8% (close to 9% in 
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children younger than 18 years), and approximately 4% of Americans (5% of children) 
experienced an asthma attack in the previous year.1 Asthma accounts for 2.1 million 
unscheduled ED visits annually, with a prevalence of 8.4% of the US population.2 The 
most likely explanation for the apparent increased prevalence is clinician and public 
awareness of the signs and symptoms of asthma that could have led to a change in 
diagnostic recognition.1 It is also likely that changes in the risk factors thought to cause 
and worsen asthma are responsible for much of the increase in asthma prevalence. 
These include increased survival rates of premature infants, as well as indoor pollutants 
due to changes in indoor living such as: 1) smoking, 2) aero allergens, 3) viral agents, 
4) molds, and 5) irritant gases. These factors appear to have more influence than 
outdoor air pollution.14 The annual death rate from asthma in the United States has 
decreased overall, however consistently higher rates have been reported for blacks 
than for whites, but not for Hispanic or Latino ethnicity.1 This difference in death rates is 
thought to be due to socioeconomic factors such as low-income and living in inner 
cities, which are related to difficulty accessing medical care.15  
Natural History 
The natural history of asthma is variable and difficult to predict for a particular 
individual.16 Children with asthma experience complete remission more frequently than 
adults; however, progression to severe disease is unusual in all age groups.17 Although 
deaths do occur from asthma, they are rare, and asthma in the absence of other 
comorbid disease does not typically affect life expectancy.18 The majority of chronic 
asthma begins in the first six years of life.19 There are at least two groups of children 
who have wheeze and asthma-like symptoms at an early age.20 One group tends to 
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have intermittent symptoms, usually in relation to viral illnesses, and then outgrow the 
symptoms as the child gets older.19 The other group, which tends to have later-onset 
and more persistent symptoms, is characterized by atopy, a positive family history of 
asthma, and an increased risk for asthma later in life.19  
Despite identification of risk factors, prospective identification of an individual's 
future asthma experience is not possible.19 Adult-onset asthma tends to have been 
undiagnosed in childhood.21 One longitudinal study found that of adults with new onset 
asthma at age 22 that had no prior clinician diagnosis of asthma, 37% had reported 
wheezing during study visits in childhood and 19% had bronchial hyper responsiveness 
by cold air bronchoprovocation at age 6.21  
Among individuals, asthma severity appears to remain stable over several years. 
A retrospective, medication-based cohort study of newly diagnosed asthmatics with mild 
disease showed they were unlikely to progress clinically over the next 5 years; only 3% 
of patients diagnosed with mild disease progressed to severe disease 5 years later.17 
Wheezing and asthma in adolescence are associated with a high rate of persistence 
into adulthood (approximately 75%).17 Similarly, adults with wheezing are more likely 
than children to experience persistent asthma.17 
Asthma Exacerbation Defined 
There is no consensus on the terminology for describing or defining 
“exacerbation,” or about how to characterize an episode’s severity.22 The NIH and other 
federal agencies examined the literature and proposed that the definition of “asthma 
exacerbation” be “a worsening of asthma requiring the use of systemic corticosteroids to 
prevent a serious outcome.”22  An exacerbation can present with wheezing, shortness of 
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breath, chest tightness or pain, breathlessness, cough, and lack of response to a quick-
acting (rescue) inhaler.23 Signs of exacerbation include the following: 1) the presence or 
absence of wheezing, 2) increased work of breathing, 3) accessory muscle use/tripod 
position, 4) impaired speaking ability, 5) level of mental status, and 6) decreased peak 
expiratory volumes and oxygen saturation.23 The degree of the signs and symptoms 
vary from each individual, but are managed the same way.23  
Asthma exacerbations can be classified as mild, moderate, severe, or life 
threatening24 (Table 1). Asthma exacerbation can be diagnosed clinically, but peak 
expiratory flow (PEF) and oxygen saturation (SpO2) can be used as objective measures 
of lung function to further support the diagnosis.23 A PEF of ≥ 70% of predicted or 
personal best and/or SpO2 of ≥95% correspond to a mild exacerbation, PEF 40-69% 
and/or SpO2 of 90-95% are moderate, PEF <40% and/or SpO2 of <90% are severe, 
and PEF <25% is life threatening.3,24 Response to nebulizer treatment and improvement 
of oxygen saturation can also support the diagnosis.23  
Table 1. Mild, moderate, and severe asthma exacerbations. 
Severity Mild Moderate Severe 
Peak Expiratory 
Flow, % 
≥70 40-69 <40 
Speech Sentences Phrases Words 
Mental status Anxious Agitated Distressed 
Accessory muscle 
use 
No Some Yes 
Oxygen 
saturation, % 
≥95 90-95 <90 
Breath sounds Expiratory wheeze Inspiratory and 
expiratory wheeze 
None/silent 
Pollart, S. M., Compton, R. M., & Elward, K. S. (2011, July 1). Management of acute asthma exacerbations. 
Retrieved August 13, 2017, from http://www.aafp.org/afp/2011/0701/p40.html#afp20110701p40-b1 
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Treatment of acute exacerbations 
In patients with a peak expiratory flow of 50 to 79% of their personal best, up to 
two treatments of two to six inhalations of short-acting beta2 agonists 20 minutes apart 
followed by a reassessment of peak expiratory flow and symptoms may be safely 
employed at home.24 Administration using a hand-held metered-dose inhaler with a 
spacer device is at least equivalent to nebulized beta2 agonist therapy in children and 
adults.24 In the ambulatory and emergency department settings, the goals of treatment 
are correction of severe hypoxemia, rapid reversal of airflow obstruction, and reduction 
of the risk of relapse.24 Multiple doses of inhaled anticholinergic medication combined 
with beta2 agonists improve lung function and decrease hospitalization in school-age 
children with severe asthma exacerbations.24 Intravenous magnesium sulfate has been 
shown to significantly increase lung function and decrease the necessity of 
hospitalization in children.24 The administration of systemic corticosteroids within one 
hour of emergency department presentation decreases the need for hospitalization, with 
the most pronounced effect in patients with severe exacerbations.24  
Airway inflammation can persist for days to weeks after an acute attack; 
therefore, more intensive treatment should be continued after discharge until symptoms 
and peak expiratory flow return to baseline.24 Systemic corticosteroids given orally serve 
as a cornerstone of acute asthma therapy. Relapse rate, length of stay, and 
hospitalization rates decline with the routine use of steroids25 (Table 2).  
Table 2. SORT (Strength of Recommendation Taxonomy) Key recommendations 
for treating asthma exacerbation. 
Recommendation Evidence Rating Comments 
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Systemic Corticosteroids 
administered w/in 1 hour of ED 
presentation decreases need for 
hospitalization25 
A (consistent, 
good-quality 
patient-oriented 
evidence) 
Largest effect noted in 
patients with severe 
asthma 
Oral and parenteral corticosteroids 
are equally effective in preventing 
hospitalization in children26 
B (inconsistent or 
limited-quality 
patient-oriented 
evidence) 
 
Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G. Corticosteroids for preventing relapse following acute 
exacerbations of asthma. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD000195. DOI: 
10.1002/14651858.CD000195.pub2. 
 
 
When prevention and control of asthma symptoms fail and exacerbation results, 
pharmacotherapy is first line treatment. These include bronchodilators such as albuterol 
and ipratropium, as well as corticosteroids such as prednisone and dexamethasone. 
During an asthma exacerbation, bronchodilators are fast-acting medications to initially 
open the airways. These are short-acting and should not be used long term.27 Chronic 
use can cause tolerance, requiring higher doses to attain symptom control, which can 
increase the risk of toxicity.28,29 Prednisone and dexamethasone are used to decrease 
inflammation in the airways, but can take several hours to elicit an effect. However, their 
effects last longer and act on a different mechanism than the bronchodilators. As with 
just about all medications, these can have side effects, issues with compliance, and can 
vary in cost, depending on choice of corticosteroid, strength, and duration of treatment.  
Prednisone has been the standard of care for systemic corticosteroid use in 
acute asthma. The first use of corticosteroids to treat acute asthma exacerbation was in 
1956.4 Development of corticosteroids that have less mineralocorticoid activity, like 
prednisone, and later those that have no mineralocorticoid activity, like dexamethasone, 
made corticosteroids more attractive therapies to use in asthma.3 However, in order for 
prednisone to be most effective in resolving the airway inflammation that persists after 
the acute symptoms have subsided, as well as prevent relapse, a full 5-day course 
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should be taken.5 Some problems that occur with this course are medication adherence 
and side effects, such as 1) nausea, 2) vomiting, and 3) trouble sleeping.5 These 
problems are the reason dexamethasone use was explored as an alternative. 
Prednisone has a short half-life of 12-36 hours.5 It is dosed at 40 to 60 mg/day 
for approximately 5 days; administered as a single or 2 divided doses.5 Common side 
effects include GI upset, irritability, anorexia, and insomnia.5 Dexamethasone is 8 times 
more potent than prednisone and has a longer half-life of 36-72 hours.6 It is dosed at 12 
mg for 1-2 days; administered as single doses.6 While side effects are similar, they tend 
to occur with less frequency and/or severity.6 Also, since they are similar in 
bioavailability and their action on asthma exacerbation, several studies have looked at 
the use of dexamethasone compared to prednisone in the treatment of acute asthma 
exacerbation and preventing relapse. Therefore, this review aims to answer the 
following questions: For treatment of adults and children with acute asthma 
exacerbation, is dexamethasone as effective as prednisolone? Are side effects and 
relapse rate similar for both medications? Is there a difference in compliance between 
the two medications? 
Methods 
To address my clinical questions, I searched PubMed with the following terms: 
‘dexamethasone AND asthma’, ‘dexamethasone AND adults AND asthma’, 
‘dexamethasone AND children AND asthma’, ‘dexamethasone AND prednisone AND 
asthma’. I also searched Embase with the following terms: ‘dexamethasone’ with ‘drug 
comparison’ subheading AND ‘asthma’ with ‘drug therapy’ subheading.  
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For my clinical review on this topic, I included randomized controlled trials, 
retrospective cohort studies, and systematic reviews. I excluded studies that compared 
other medications to prednisone or dexamethasone, other types of corticosteroids (ie. 
ICS), other routes of administration of either dexamethasone or prednisone, and those 
that did not address asthma exacerbation. Bias was evaluated with the Cochrane Risk 
of Bias Tool and the GRADE (Grades of Recommendation, Assessment, Development 
and Evaluation) system. 
Results  
This review included evaluation of a Cochrane systematic review of randomized 
trials, as well as three studies that were not included in the systematic review. Summary 
tables of study results, outcomes, and bias evaluations are included (Tables 3,4,5). 
Rehrer et al. (2016) conducted a prospective, triple-blind, randomized, controlled 
non-inferiority trial that aimed to compare a single dose of dexamethasone to a pulsed 
dose of prednisone for adults with acute asthma exacerbations.2 Three hundred 
seventy-six adult emergency department patients (aged 18 to 55 years) were assigned 
to either a single oral dose of 12 mg of dexamethasone plus 4 placebo pills or 5 oral 
doses of 60 mg prednisone capsules. The primary outcome was rate of relapse, as 
defined by an unscheduled return visit to a health care provider for additional treatment 
for persistent or worsening asthma within 14 days. Outcomes were assessed by follow 
up telephone interview at 2 weeks. Relapse occurred in 12.1% of the dexamethasone 
group and 9.8% of the prednisone group, a difference of 2.3%. The 95% confidence 
limits (-4.1% to 8.6%) fell outside the pre-specified 8% non-inferiority threshold. The 
study failed to show non-inferiority of single oral dose dexamethasone compared to a 
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five-day course of oral prednisone by a very narrow margin (0.6%). Selection bias was 
addressed by having well-balanced baseline characteristics between the two study 
groups, as well as utilizing a randomization table maintained by the pharmacy and 
having both medications identical in appearance. The study had no evidence of 
performance bias; patients, physicians, and researchers were blinded to study arm 
assignment. There was no detection bias as the data analysis team was blinded to 
allocation arm until the results were final and the blind was lifted in the article-writing 
phase. Attrition bias was addressed by using an intention to treat analysis and “worst 
case” sensitivity analyses to assess the robustness of the result, given that the lost to 
follow up rate was near 20%. The study appeared to present all data and outcomes 
despite the fact that they did not yield their expected result, thus addressing reporting 
bias; they provided discussion of limitations to the study that may have contributed to 
those results.2 
Cronin et al., 2016 conducted a randomized, open-label, non-inferiority trial that 
examined whether a single dose of oral dexamethasone was not inferior to prednisolone 
in the emergency department (ED) treatment of asthma exacerbations in children.10 
Two hundred twenty-six study participants aged 2 to 16 years old with a known asthma 
diagnosis or at least 1 previous episode of ß2-agonist–responsive wheeze who 
presented to a tertiary pediatric ED were assigned to either a single oral dose of 0.3 
mg/kg of dexamethasone or 3 oral doses of 1 mg/kg per day of prednisolone. The 
primary outcome measure was the mean Pediatric Respiratory Assessment Measure 
(PRAM) score performed on day 4. The score consists of 5 components and has a 
maximum total of 12 points: suprasternal retractions (0 to 2), scalene muscle 
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contraction (0 to 2), air entry (0 to 3), wheezing (0 to 3), and SaO2 (0 to 2). Secondary 
outcome measures included requirement for further steroids, vomiting of study 
medication, hospital admission, and unscheduled return visits to a health care 
practitioner within 14 days. Results showed no difference in mean PRAM scores at day 
4 between the dexamethasone and prednisolone groups (0.91 versus 0.91; absolute 
difference 0.005; 95% CI –0.35 to 0.34). Fourteen patients vomited at least 1 dose of 
prednisolone compared with no patients in the dexamethasone group. Sixteen children 
(13.1%) in the dexamethasone group received further systemic steroids within 14 days 
after trial enrollment compared with 5 (4.2%) in the prednisolone group (absolute 
difference 8.9%; 95% CI 1.9% to 16.0%). There was no significant difference between 
the groups in hospital admission rates or the number of unscheduled return visits to a 
health care practitioner. The study demonstrated that in children with acute 
exacerbations of asthma, a single dose of oral dexamethasone (0.3 mg/kg) is not 
inferior to a 3-day course of oral prednisolone (1 mg/kg per day) as measured by the 
mean PRAM score on day 4.  
Selection bias was addressed with using a randomization design that generated 
numeric codes. Sealed envelopes were pre-randomized and kept in a locked storage 
cabinet. Baseline demographic characteristics, except for sex distribution, being similar 
between the 2 groups. There were significantly more male patients in the prednisone 
group (74.6% versus 61.8%; P=.03). There was no significant difference between the 
study groups in symptom duration or in the PRAM score at initial ED clinical 
assessment. Performance bias was addressed with this being a blinded study, with the 
physician assessing primary outcome blinded to treatment allocation. Detection bias 
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was addressed with the primary outcome using an objective measure in the PRAM 
score; and the number of patients admitted to the hospital where inpatient treatment 
may have differed from outpatient treatment was addressed by the fact that that number 
was similar in both groups. Attrition bias was to be addressed by the study aiming to 
recruit a sufficient number of patients to allow a loss to follow-up rate of 10%, however 
their actual rate was not reported or discussed. It was also addressed with an intention-
to-treat analysis for participants who vomited study medication. Reporting bias was 
addressed with several tables of detailed results of primary and secondary outcomes, 
as well as summary tables and discussion of the limitations of the study.10 
Watnick et al., 2015 conducted a retrospective cohort study that examined 
relapse rates in a large population of children treated for acute asthma exacerbations 
during an era of prednisone and prednisolone use compared with an era of 
dexamethasone use.13 Data were extracted from electronic medical records of all 
patients 3 to 17 years old presenting to an urban, tertiary care children's hospital ED 
from January 2006 through December 2014 with a primary International Classification of 
Diseases, Ninth Revision code (493.00) for acute asthma. They identified patients seen 
in the ED, treated with systemic corticosteroids, and subsequently discharged. Within 
that group, they identified those who returned within 72 hours for continued asthma 
symptoms. Out of 13,518 unique patient ED visits, 7,130 patients (52.7%) were 
identified who received oral prednisone or prednisolone and 1,639 (12.1%) who 
received oral dexamethasone. There were 143 relapses (2.01%) in patients receiving 
oral prednisone or prednisolone and 21 (1.28%) in those receiving oral dexamethasone 
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(P = .05, absolute risk reduction 0.73%, relative risk reduction 36%). No demographic 
characteristics were associated with relapse in multivariable models.  
Confounding evidence was addressed with the χ2 test that was used to compare 
relapse rates of patients receiving oral dexamethasone with those receiving oral 
prednisone or prednisolone, and multivariable logistic regression was used to examine 
for associations of corticosteroid formulation with relapse, adjusted for sex, age, race, 
ethnicity, and insurance type.13 No demographic characteristics were associated with 
relapse in multivariable models.13 To avoid double counting of patients, for patients with 
multiple ED visits within 72 hours, only the first return visit was analyzed. Data from 
4,749 patients (35.1%) who received no corticosteroid or an intravenous formulation of 
corticosteroid were not included in the analysis.13 Additional bias was present due to 
lack of information regarding the severity of a patient's asthma exacerbation and 
detailed asthma characteristics (eg, intermittent vs persistent, presence of smoke 
exposure, and influenza vaccination status). In addition, any patient with an incorrect 
International Classification of Diseases, Ninth Revision code not reflective of acute 
asthma as the primary cause for ED visit was missed in the analysis.13 There was no 
evidence of reporting bias; all results were reported.13 
A 2016 Cochrane systematic review assessed the efficacy and safety of any 
dose or duration of oral steroids (prednisone vs dexamethasone). The authors 
evaluated 18 studies that looked at higher versus lower doses of prednisolone (n = 4); 
longer versus shorter courses of prednisolone (n = 3) or dexamethasone (n = 1); 
tapered versus non-tapered courses of prednisolone (n = 4); and prednisolone versus 
dexamethasone (n = 6). Eligibility criteria included parallel randomized controlled trials 
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(RCTs), irrespective of blinding or duration, that evaluated one dose or duration of oral 
steroid versus any other dose or duration, for management of asthma exacerbations; 
studies involving both adults and children with asthma of any severity, in which 
investigators analyzed adults and children separately; any other co-intervention in the 
management of an asthma exacerbation allowed, provided it was not part of the 
randomized treatment; and studies reported as full text, those published as abstract 
only and unpublished data. Search methods included trials from the Cochrane Airways 
Group Specialized Register (CAGR), ClinicalTrials.gov (www.ClinicalTrials.gov), the 
World Health Organization (WHO) trials portal (www.who.int/ictrp/en/) and reference 
lists of all primary studies and review articles. A detailed list of search terms and filters 
was provided in this review.  
Primary outcomes were admission/readmission to the hospital, asthma 
symptoms at the end of steroid course, and serious adverse events. In studies 
comparing dexamethasone to prednisone, the OR for hospital readmission during the 
follow up period was 0.35 (very low quality) in adults and 0.44 (low quality) in children; 
OR for asthma symptoms at the end of the steroid course was 0.44 (low quality) for 
return to normal activity within 3 days, 1.32 (very low quality) for ED visit after 
discharge, and 1.85 (very low quality) for an unscheduled visit to a PCP in adults and 
0.85 (low quality) in children; the OR for serious adverse events was not evaluated in 
adults and was not estimable in children. For two of the primary outcomes - hospital 
admission and serious adverse events - events were too infrequent to permit 
conclusions about the superiority of one treatment over the other, or their equivalence.9 
Researchers in the included studies reported asthma symptoms in different ways and 
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rarely used validated scales, again limiting the conclusions.9 Risk of bias in each study 
was thoroughly assessed in detail in the body of the paper, as well as summarized in a 
table. Two review authors independently screened the search results for included trials, 
extracted numerical data and assessed risk of bias; all data were cross-checked for 
accuracy.9 Disagreements were resolved by discussion with the third review author or 
with an external advisor.9 Dichotomous data such as odds ratios (ORs) or risk 
differences (RDs) were analyzed using study participants as the unit of analysis; 
continuous data was analyzed as mean differences (MDs).9 A random-effects model 
was used, and a stratified fixed-effect analysis was carried out to address statistical 
heterogeneity.9  
All outcomes were rated using the GRADE system and presented results in 
'Summary of findings' tables.9 Results data and analyses for each outcome, including 
raw data for each study, was included in the review. Overall, they found no convincing 
evidence of differences in outcomes between a higher dose or longer course and a 
lower dose or shorter course of prednisolone or dexamethasone, or between 
prednisolone and dexamethasone.9 Included studies were generally of reasonable 
methodological quality.9 Review authors assessed most outcomes in the review as 
having low or very low quality, meaning they were not confident in the effect estimates9 
(Table 3). The predominant reason for downgrading was imprecision, but indirectness 
and risk of bias also reduced their confidence in some estimates.9 
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Table 3. Summary of Findings with GRADE evaluation of Prednisone vs 
Dexamethasone in Adults and Children. 
 
Normansell, R., Kew, K. M., & Mansour, G. (2016). Different oral corticosteroid regimens for acute asthma. Cochrane 
database of systematic reviews. doi:10.1002/14651858.CD011801.pub2 
aOnly 1 study contributed to this outcome with very few events reported in total, resulting in an imprecise estimate 
with confidence intervals including both important harms and benefits of either regimen. Downgraded twice for 
imprecision 
bOnly contributing study judged to be at high risk of attrition bias because of post-randomization exclusions and large 
numbers lost to follow-up. Downgraded once for risk of bias 
cOnly one study contributed to this outcome with imprecise estimate and confidence intervals not completely 
excluding the possibility of no differences. Downgraded once for imprecision 
dThe 2 studies contributing most events to this outcome were considered to be at high or unclear risk of selection,  
performance, and detection bias. In addition, one study allowed 19 participants to enroll more than once in the study. 
Downgraded once for risk of bias 
eConfidence intervals include possible harms or benefits of either intervention. Downgraded once for imprecision 
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Table 4. Summary of study results and outcomes. 
 
Table 5. Cochrane Risk of Bias Evaluation. 
 
Discussion 
After reviewing these papers, the overall conclusion is that dexamethasone has 
the potential to be equivalent, if not slightly inferior, to prednisone in the treatment of 
acute asthma exacerbations in adults and children. There are more studies in the 
pediatric population regarding this topic and they have more consistently demonstrated 
18	
	
that dexamethasone is as effective as prednisone.10,13 The few studies that have been 
conducted on adults have also shown this to be true.2 However, the Cochran systematic 
review of 6 other studies comparing dexamethasone and prednisone in adults and 
children concluded that the evidence presented was not strong enough to indicate 
whether the usual second-line option, dexamethasone, is better or worse than 
prednisolone. These findings address my first question: For treatment of adults and 
children with acute asthma exacerbation, is dexamethasone as effective as 
prednisolone? 
Outcomes varied among the studies reviewed, with many studies using relapse 
rate as the primary outcome, as there is no consensus on a uniform measure of 
symptom severity. Relapse rate was either defined as an unscheduled return visit within 
14 days or 72 hours.2,13 The national relapse rate for asthma exacerbation in the United 
States is 16%.30 Rehrer 2016 showed a relapse rate of 12.1% for the dexamethasone 
group and 9.8% in the prednisone group. Watnick 2016 showed a relapse rate of 1.28% 
in the dexamethasone group and 2.01% in the prednisone group. Change in symptoms 
was measured using an objective reporting scale, the PRAM score.10 While the PRAM 
score is an objective measure of symptoms, the Cronin 2016 study is the only study to 
use it to date; other studies that have reported measures of symptom severity were not 
shown to be objective and they have been variable across studies, making it difficult to 
compare them with other studies.10 Secondary outcomes were identified as increased 
steroid requirement, side effects, and hospital admission. More patients in the 
dexamethasone group received additional steroid therapy during the 2-week study 
period, but after the day 4 PRAM score; this was suggested to be due to physician bias 
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toward using prednisone as first line treatment, even though there was no significant 
difference in asthma severity between the two study arms.10 Subjects in the prednisone 
group vomited the study medication, whereas none in the dexamethasone group did, 
suggesting increased side effects and decreased palatability of prednisone.10 No other 
adverse events attributable to the study medications were noted.10 Hospital admission 
was equal among both groups.10 These findings address my question: Are side effects 
and relapse rate similar for both medications? 
[insert results and RoB tables] 
One of the largest benefits of a single dose of oral dexamethasone comes from 
the likelihood of improved compliance. The medication may be administered in the ED 
or office setting without any requirement for filling a prescription and then receiving the 
medication as prescribed at home. The average cost of a 5-day course of 40 mg oral 
prednisone in the US is $29.14, compared with the cost of 1-2 days of 12 mg oral 
dexamethasone at $2.14 – $4.28. Compliance rates after discharge of patients who had 
been hospitalized for asthma were studied and adherence at 7 days for oral and inhaled 
corticosteroids was 50%; poor adherence significantly predicted significantly worsened 
symptom control.31 Dexamethasone has been found to be close in efficacy to 
prednisone in the treatment of asthma exacerbation, and has a similar side effect profile 
and relapse rate. In patients where cost or compliance could be an issue, 
dexamethasone could be a comparable alternative. The Rehrer study, by a small 
margin, did not demonstrate non-inferiority of a single dose of dexamethasone to 5 days 
of prednisone for adult patients with mild to moderate acute asthma exacerbations for 
prevention of relapse. However, enhanced compliance and convenience may support 
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the use of a single oral dose of dexamethasone regardless, suggesting that the use of a 
one-time dose of dexamethasone may lead to fewer relapses in patients who are 
unlikely to fill or take the entire course of steroids. These findings addressed my final 
question: Is there a difference in compliance between the two medications? 
Overall, the studies reviewed demonstrated strengths in study design with 
blinding, well-balanced baseline characteristics among study groups, comprehensive 
literature searches, objective outcome measures, and low risk of bias. They also 
demonstrated that dexamethasone can be beneficial in certain patient populations and 
improve compliance and convenience, thus possibly decreasing relapse rates. 
Limitations of these studies include the lack of studies on this specific topic; 
variable or unidentified asthma severity; variable outcomes and evaluation tools which 
have led to low quality data; high loss to follow up rate; low participant numbers; as well 
as variable ages being assessed. Most studies recruited participants from the ED 
setting, which limits applicability to patients that present to their PCP.  
Conclusion 
These studies have demonstrated that dexamethasone is a promising 
comparable alternative to prednisone in the treatment of asthma exacerbation in both 
adults and children. However, in order for this possibility to be readily adopted into 
guidelines and clinical practice, higher quality and more consistent data needs to be 
obtained. If possible, an objective measure of asthma exacerbation and response to 
treatment, as well as standard outcome measures, should be defined and summarily 
used in future studies.  
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More research is needed in adults, larger study populations should be used, and 
improved steps to minimize loss follow up and/or better tracking of loss to follow up. It is 
important to identify the most effective treatment for asthma exacerbation; while 
prevention is key, sometimes this cannot be avoided. More medication options that are 
just as effective, but safer and more convenient, would be beneficial to address issues 
such as adherence, side effects, palatability, cost, as well as decreased relapse, 
hospital admissions, prolonged course/symptoms, and long term effects. Uncontrolled 
asthma has a very high healthcare cost, not to mention the cost on quality of life. The 
ultimate goal is to maximize recovery while minimizing side effects and relapse. 
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